VY1706

June 29, 2026: Voyager Therapeutics, Inc. (NASDAQ: VYGR) announced a late-breaking “Developing Topics” poster presentation on VY1706 at the Alzheimer’s Association International Conference (AAIC) in London (July 12–15, 2026). The poster (“IND-enabling GLP NHP study of VY1706, a BBB-crossing AAV gene therapy targeting tau in Alzheimer’s,” #Monday-1207) is scheduled for Monday, July 13, 2026 (7:30 a.m.–4:15 p.m. GMT) and will be posted on Voyager’s website.

Voyager also disclosed it recently received FDA IND clearance for VY1706, enabling initiation of a clinical trial in adults with early Alzheimer’s disease; first dosing is expected in the second half of 2026.

VY1706 is a one-time IV AAV gene therapy delivering a vectorized siRNA targeting MAPT mRNA to reduce intracellular and extracellular tau. In a 3-month GLP non-human primate toxicology study, Voyager reported favorable tolerability with no adverse clinical pathology or histopathology findings up to the highest tested dose (5E13 vg/kg) after a single IV dose, and up to 75% tau reduction in key NHP brain regions.